Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
In this phase clinical trail, we evaluate the efficacy and feasibility of azacytidine and
venetoclax as leukemia debulking treatment followed by reduced intensity conditioning regimen
consisting of Fludarabine + Busulfan + Melphalan as salvage treatment in patients with
refractory AML .